JP2023529701A5 - - Google Patents
Info
- Publication number
- JP2023529701A5 JP2023529701A5 JP2022576178A JP2022576178A JP2023529701A5 JP 2023529701 A5 JP2023529701 A5 JP 2023529701A5 JP 2022576178 A JP2022576178 A JP 2022576178A JP 2022576178 A JP2022576178 A JP 2022576178A JP 2023529701 A5 JP2023529701 A5 JP 2023529701A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- group
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025137145A JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036622P | 2020-06-09 | 2020-06-09 | |
| US63/036,622 | 2020-06-09 | ||
| US202063111429P | 2020-11-09 | 2020-11-09 | |
| US63/111,429 | 2020-11-09 | ||
| PCT/US2021/036657 WO2021252661A1 (en) | 2020-06-09 | 2021-06-09 | Allosteric egfr inhibitors and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137144A Division JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137145A Division JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529701A JP2023529701A (ja) | 2023-07-11 |
| JP2023529701A5 true JP2023529701A5 (enExample) | 2024-06-19 |
| JP7785701B2 JP7785701B2 (ja) | 2025-12-15 |
Family
ID=78846544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576178A Active JP7785701B2 (ja) | 2020-06-09 | 2021-06-09 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137145A Pending JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A Pending JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137145A Pending JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A Pending JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230212171A1 (enExample) |
| EP (1) | EP4161516A4 (enExample) |
| JP (3) | JP7785701B2 (enExample) |
| KR (1) | KR20230033645A (enExample) |
| CN (1) | CN115811977A (enExample) |
| AU (1) | AU2021289729A1 (enExample) |
| BR (1) | BR112022025139A2 (enExample) |
| CA (1) | CA3181982A1 (enExample) |
| CO (1) | CO2022019316A2 (enExample) |
| EC (1) | ECSP22098041A (enExample) |
| IL (1) | IL298935A (enExample) |
| JO (1) | JOP20220332A1 (enExample) |
| MX (1) | MX2022015739A (enExample) |
| SA (1) | SA522441639B1 (enExample) |
| WO (1) | WO2021252661A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| JP2025521540A (ja) * | 2022-06-21 | 2025-07-10 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 縮合二環式ｅｇｆｒ阻害剤およびその使用の方法 |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005021963A1 (de) * | 2005-05-12 | 2006-11-23 | Aicuris Gmbh & Co. Kg | Substituierte Dihydropyrazolotriazinone |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| WO2008130581A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| US8394802B2 (en) * | 2008-09-19 | 2013-03-12 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases |
| HK1252693A1 (zh) * | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| IL279800B2 (en) * | 2018-06-29 | 2024-02-01 | Hoffmann La Roche | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use |
| CN112839937B (zh) * | 2018-08-16 | 2023-08-22 | 韩国化学研究院 | 异吲哚啉-1-酮衍生物、其制备方法及其用途 |
-
2021
- 2021-06-09 CN CN202180041075.2A patent/CN115811977A/zh active Pending
- 2021-06-09 CA CA3181982A patent/CA3181982A1/en active Pending
- 2021-06-09 JP JP2022576178A patent/JP7785701B2/ja active Active
- 2021-06-09 EP EP21821203.3A patent/EP4161516A4/en active Pending
- 2021-06-09 IL IL298935A patent/IL298935A/en unknown
- 2021-06-09 KR KR1020227043942A patent/KR20230033645A/ko active Pending
- 2021-06-09 BR BR112022025139A patent/BR112022025139A2/pt unknown
- 2021-06-09 AU AU2021289729A patent/AU2021289729A1/en active Pending
- 2021-06-09 MX MX2022015739A patent/MX2022015739A/es unknown
- 2021-06-09 US US18/000,722 patent/US20230212171A1/en active Pending
- 2021-06-09 WO PCT/US2021/036657 patent/WO2021252661A1/en not_active Ceased
-
2022
- 2022-12-07 SA SA522441639A patent/SA522441639B1/ar unknown
- 2022-12-08 JO JOJO/P/2022/0332A patent/JOP20220332A1/ar unknown
- 2022-12-28 EC ECSENADI202298041A patent/ECSP22098041A/es unknown
- 2022-12-30 CO CONC2022/0019316A patent/CO2022019316A2/es unknown
-
2025
- 2025-08-20 JP JP2025137145A patent/JP2025170326A/ja active Pending
- 2025-08-20 JP JP2025137144A patent/JP2025168374A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519783A5 (enExample) | ||
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2023520333A5 (enExample) | ||
| RU2440330C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2022516883A5 (enExample) | ||
| JP2021512059A5 (enExample) | ||
| JP2022547952A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2022515198A5 (enExample) | ||
| JP2019518741A5 (enExample) | ||
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| JP2018504418A5 (enExample) | ||
| DK2326329T3 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2020503299A5 (enExample) | ||
| JP2021516232A5 (enExample) | ||
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| AU2016257816A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| JP2020507582A5 (enExample) | ||
| JP2018505880A5 (enExample) | ||
| JP2019507114A5 (enExample) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2015529194A5 (enExample) | ||
| JP2020500869A5 (enExample) | ||
| KR20100131446A (ko) | Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |